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Summary
Although COPD is a debilitating pulmonary condition, many studies have shown awareness
of the disease to be low. This article presents data on attitudes and beliefs about COPD
in subjects with respiratory symptoms participating in the BREATHE study in the Middle
East and North Africa region. This study was a large general population survey of COPD
conducted in ten countries of the region (Algeria, Egypt, Jordan, Lebanon, Morocco, Saudi
Arabia, Syria, Tunisia, Turkey and United Arab Emirates), together with Pakistan, using
a standardised methodology. A total of 62,086 subjects were screened, of whom 2,187
fulﬁlled the “epidemiological” deﬁnition of COPD. A detailed questionnaire was administered
to these subjects, which documented knowledge about the disease, attitudes to care,
beliefs about COPD and satisfaction with treatment. 1,392 subjects were analysable.
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Overall, 58.6% of subjects claimed to be very well or adequately informed about their
respiratory condition. Two-thirds of subjects reported receiving information about COPD
from their physician and 10.6% from television; the internet was cited by 6% and other
health professionals or patient associations by <1%. Several inappropriate beliefs were
identiﬁed, with 38.9% of respondents believing that there were no truly effective treatments,
73.7% believing that their respiratory condition would get progressively worse regardless of
treatment and 29.6% being unsure what had caused their respiratory problems. Although
81% of respondents believed that smoking was the cause of most cases of COPD in general,
only 51% accepted that it was the cause of their own respiratory problems. Treatment
satisfaction was relatively high, with 83.2% of respondents somewhat or very satisﬁed
with their physician’s management, in spite of the fact that only 47.5% considered that
their physician’s advice had helped them manage their respiratory symptoms a lot. In
conclusion, awareness of COPD in the region is suboptimal and treatment expectations are
undervalued. Better patient education and more effective patient physician communication
are clearly required.
© 2012 Elsevier Ltd. All rights reserved.
Introduction
Chronic Obstructive Pulmonary Disease (COPD) is a common
respiratory condition characterised by progressive and
potentially severe airway obstruction which may manifest
as breathlessness, excessive sputum production, and chronic
cough,1 and covers both chronic bronchitis (persistent
cough and sputum production) and emphysema (breath-
lessness and difﬁculty coughing). The Global Initiative for
Obstructive Lung Disease (GOLD) has published practice
guidelines for the diagnosis of COPD based on clinical
symptoms conﬁrmed by lung function testing and also for
its treatment.2,3
Although COPD is common, potentially highly invalidating,
with patients with severe disease requiring oxygen therapy,
and carries a high mortality, for example being the third
most frequent cause of death in the USA,4 awareness of
the disease by the general public is low and COPD has a
much lower visibility than other common chronic diseases
such as asthma or diabetes. This lack of awareness on the
part of patients, and perhaps to some degree as well on
the part of health professionals, represents a barrier to
more timely diagnosis, implementation of optimal standards
of care and appropriate prevention strategies, for example
with respect to smoking, which is the principal risk factor
for COPD.
There is little available information on how patients
with COPD perceive their disease, the extent of their
knowledge about their condition and their attitudes to
treatment. However, the international Confronting COPD
surveys, performed in North America and Europe in 2000, did
systematically document many of these aspects. The data
from the USA have been published5 and these showed that
although subjects with COPD were generally satisﬁed with
their treatment, their expectations were rather low, since
many were being treated sub-optimally and experiencing
signiﬁcant disability, and that these subjects tended to
underestimate the degree to which the disease could be
managed. It was concluded that there was a need for better
education and patient physician dialogue to improve COPD
management.
The international BREATHE survey was recently conducted
in general populations of ten countries in the Middle
East and North Africa, as well as Pakistan.6 This study
identiﬁed a large cohort of individuals aged 40 years
fulﬁlling an epidemiological deﬁnition of COPD and collected
information from these subjects on their perceptions of their
disease and its treatment, including data on their attitudes
and beliefs with respect to their respiratory condition. This
information was collected using a similar questionnaire to
that used in Confronting COPD , which allows the ﬁndings to
be compared with those of the latter study.
Methods
The BREATHE study was a cross-sectional epidemiological
survey of COPD conducted in eleven countries in the MENA
region (Algeria, Egypt, Jordan, Lebanon, Morocco, Pakistan,
Saudi Arabia, Syria, Tunisia, Turkey and UAE) between
June 2010 and December 2011. A detailed description of
the methodology used in the study can be found in another
article in this supplement.6 The present article presents the
data obtained on attitudes and beliefs about COPD.
Study sample
A general population sample of 10,000 subjects was
generated from random telephone numbers of each country
or zone of the MENA region. All subjects (men or women)
aged 40 years who agreed to participate in the study
were included and were proposed a structured telephone
interview. Subjects not domiciled in the country or zone in
question, or those of foreign origin resident in the country
for <6 months at the time of the study were excluded
from the study, as were subjects with comorbid mental
illness.
Data collection
When initial telephone contact with each subject was
established, the interviewer explained the goal of the study
and the next steps. Subjects who agreed to participate in
the study completed a ﬁrst screening questionnaire which
collected data on demographics, respiratory symptoms and
smoking habits.6 8
Subjects were considered to have symptomatic COPD
if they fulﬁlled the two criteria for the epidemiological
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Box 1. KNOWLEDGE AND EDUCATION
55. Based on what you know or have heard, what is the underlying condition that causes your Respiratory
Condition?
Multiple responses possible
(a) Inﬂammation of airways, (b) Redness/swelling of airways, (c) Allergies, (d) Smoking,
(e) Bronchoconstriction/tightening of airway muscles, (f) Pollution, (g) Work-related exposure, (h) Other,
(i) Not sure
56. How well informed do you feel you are about your Respiratory Condition and its treatment?
Four response modalities:
a (very well informed ) to d (very poorly informed )
57. How well do you feel that you understand the best ways to manage your Respiratory Condition? Would
you say that you understand them …?
Five response modalities:
a (completely ) to e (not at all )
58. How much need do you think there is for better education of people with Respiratory Conditions about
their condition and its treatment? Do you think there is a …
Four response modalities:
a (strong need ) to d (no need at all )
59. How much need do you think there is for better education of doctors and other health professionals
about respiratory conditions? Do you think there is a …
Four response modalities:
a (strong need ) to d (no need at all )
60. Where do you get most of your information about your Respiratory condition?
(a) Doctors, (b) Nurses, (c) Other health professionals, (d) Other patients, (e) Patient organisations,
(f) Books, (g) Library, (h) Internet, (i) TV/Cable, (j) Rdio, (k) Newspapers, (l) Magazines, (m) Family and
friends, (n) Other
deﬁnition of COPD used in this study and outlined in
the methodology paper.6 The ﬁrst criterion was EITHER
a diagnosis of COPD, emphysema or chronic bronchitis
OR the presence of coughing with phlegm or sputum
(productive cough), breathlessness or symptoms consistent
with chronic bronchitis. The second criterion was a
lifetime smoking exposure of 10 pack·years. Subjects
in the COPD population were considered as positively
screened and were invited to undergo a second more
detailed telephone questionnaire on the disease (detailed
COPD questionnaire). This second questionnaire consisted
of 77 questions collecting information on risk factors,
comorbidities, disease history, clinical symptoms and burden
and management of the disease. Many of the items in
this questionnaire, and notably those related to burden of
disease, were adopted from the Confronting COPD study
questionnaire.9
Overall symptom severity was assessed with the COPD
Assessment Test (CAT),10,11 an eight-item patient-reported
outcome measure which scores severity on a forty-point
ordinal scale (0: no impairment; 40: high impairment).
Information was also collected on disease exacerbations
in the previous six months. Since the BREATHE study
questionnaire addressed members of the general popula-
tion in non-medical terms, the number of exacerbations
was not explicitly documented and the presence of
an exacerbation was thus determined operationally. An
exacerbation was taken to have occurred in the previous
six months if the subject fulﬁlled any of the following
criteria:
• Criterion 1: In the last 6 months, have you been told
by your physician that you have had worsening of your
“Respiratory Condition”? YES
• Criterion 2: In the last 6 months, have you been told by
your physician that you have had acute bronchitis? YES
• Criterion 3: In the last 6 months, what aspects of your
“Respiratory Condition” have worsened? (cough during the
daytime, cough during the night, phlegm, breathlessness
or shortness of breath and fatigue, ability to perform
regular activities) At least two symptoms cited
Attitudes and beliefs of respondents concerning COPD
were documented through a series of questions in the
detailed COPD questionnaire which are listed in Boxes 1 3.
Summary variables
Three summary variables were deﬁned operationally to
represent knowledge about COPD, optimistic beliefs and
treatment satisfaction. These are deﬁned as listed in
Table 1.
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Box 2. BELIEFS ABOUT COPD AND ITS TREATMENT
61. Now I’m going to read you a series of statements and I would like you to tell me whether you agree
strongly, agree somewhat, disagree somewhat or disagree strongly with the statement?
Five response modalities (including ‘Don’t know’ )
a. There are no truly effective treatments for Respiratory Condition
b. Smoking is the cause of most cases of Respiratory Condition
c. With proper treatment of Respiratory Condition, progressive increase in breathlessness can be slowed
d. Respiratory Condition tends to get worse as you get older, regardless of treatment
e. People with Respiratory Condition have better control of their disease than ﬁve years ago
f. With proper treatment most people with Respiratory Condition can lead a full and active life
62. I would like to know whether you agree or disagree with each of the following statements about
treatment. Do you agree strongly, agree somewhat, disagree somewhat or disagree strongly that …
Five response modalities (including ‘Not sure’ )
a. Inhalers are effective in providing relief from symptoms
b. I always carry an inhaler with me
c. Having to take medicine twice a day is more convenient than 3 or 4 times a day
d. If it was more convenient to take my medication, I would be better about taking it when I should
e. Being able to sleep through the night is very important to me
f. Taking so many medicines in different inhalers is inconvenient
g. I want a medication that will allow me to maintain a normal activity level
h. My current medication schedule makes it difﬁcult to lead an active life
Box 3. ATTITUDES TO TREATING PHYSICIAN
39. Would you say that you follow your doctor’s advice on the management and treatment of your
Respiratory Condition?
Five response modalities:
a (all of the time ) to e (never )
40. How much has your doctor’s advice helped improve your ability to manage your respiratory symptoms?
Has it improved …?
Four response modalities:
a (a lot ) to d (not at all )
41. Overall, how satisﬁed are you with your doctor’s management and treatment of your Respiratory
Condition? Are you …
Four response modalities:
a (very satisﬁed ) to d (very dissatisﬁed )
42. Based on your experience with the doctor you see most often for your condition, would you strongly
agree, somewhat agree, somewhat disagree or strongly disagree with the following statements?
a. My doctor is genuinely concerned about helping me
b. My doctor thinks my condition is my fault
c. My doctor doesn’t think he or she can do anything to relieve my symptoms
d. My doctor is very knowledgeable about my condition and its treatment
e. My doctor does not understand what it is like to suffer from my condition
f. My doctor really involves me in decisions about my treatment
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Table 1
Deﬁnitions of the summary variables knowledge, optimistic beliefs and satisfaction. The question numbering corresponds
to that used in Boxes 1 to 3
Summary variable Modality Source question Response
Knowledge Informed Q56. How well informed do you feel you are about
your Respiratory Condition and its treatment?
(a) Very well informed
OR
(b) Adequately informed
Not informed (c) Less than adequately informed
OR
(d) Very poorly informed
Optimistic beliefs Yes Q61. At least FOUR of the following:
a. There are no truly effective treatments for
Respiratory Conditions
Somewhat OR Strongly Disagree
c. With proper treatment of Respiratory Condition,
progressive increase in breathlessness can be
slowed
Somewhat OR Strongly Agree
d. Respiratory Condition tends to get worse as you
get older, regardless of treatment
Somewhat OR Strongly Agree
e. People with Respiratory Condition have better
control of their disease than ﬁve years ago
Somewhat OR Strongly Agree
f. With proper treatment most people with
Respiratory Condition can lead a full and active life
Somewhat OR Strongly Agree
No All other subjects
Satisfaction Satisﬁed Q41. Overall, how satisﬁed are you with your
doctor’s management and treatment of your
Respiratory Condition?
(a) Very satisﬁed
OR
(b) Somewhat satisﬁed
Dissatisﬁed (c) Somewhat dissatisﬁed
OR
(c) Very dissatisﬁed
Statistical analysis
Data presentation is principally descriptive, with continuous
variables being presented as mean values ±SEM and
categorical variables as frequency counts (%). Missing data
were not replaced and the relatively few subjects for whom
data were missing were excluded from the calculation of
frequency rates. Multivariate logistic regression analysis was
used to determine potential associations between on the
one hand, demographic (age and gender), smoking (current
or ex-smoker), clinical (CAT score and exacerbation history)
and treatment (bronchodilator use) variables and, on the
other, the summary variables of knowledge, optimistic
beliefs and satisfaction as deﬁned above.
Results
Study sample
A total of 62,086 subjects completed the screening ques-
tionnaire. Of this population, 8,850 subjects reported at
least one COPD-related symptom, namely productive cough
or breathlessness. A total of 2,187 subjects fulﬁlled the
epidemiological deﬁnition of COPD,6 of whom 1,392 (63.6%)
completed the detailed COPD subject questionnaire (from
37.0% in Pakistan to 89.5% in Morocco) and constituted
the study population. No relevant differences in terms
of age, gender and COPD symptoms (productive cough,
breathlessness or symptoms consistent with chronic bron-
chitis) were found when comparing the COPD popula-
tion who completed the detailed questionnaire with all
2,187 subjects who fulﬁlled the epidemiological deﬁnition
of COPD.
The demographic features of the COPD population are
presented in Table 2. Three-quarters (75.6%) of the
study population were male (from 49.5% in Lebanon to
96.2% in Algeria). The majority of subjects were married
(89.6% overall, ranging from 79.8% in Lebanon to 100% in
the UAE). With respect to educational level, 19.3% had
a university degree, a further 31.6% had completed high
school, whereas 38.3% had never been to high school. Nearly
one half (46.6%) were in full or part time employment and
only ten subjects overall (0.8%) claimed to be unable to work
due to illness or disability. Smoking 10 pack·years was part
of the epidemiological deﬁnition of COPD and around two-
thirds of subjects were current smokers at the time of the
survey (range: 48.5% in Algeria to 82.4% in the UAE).
BREATHE study: Attitudes and beliefs about COPD in the MENA region S65
Ta
bl
e
2
D
em
og
ra
ph
ic
ch
ar
ac
te
ri
st
ic
s
of
th
e
CO
PD
po
pu
la
ti
on
by
co
un
tr
y
Al
ge
ri
a
Eg
yp
t
Jo
rd
an
Le
ba
no
n
M
or
oc
co
Pa
ki
st
an
Sa
ud
iA
ra
bi
a
Sy
ri
a
Tu
ni
si
a
Tu
rk
ey
U
AE
To
ta
l
Ag
e
gr
ou
p
10
5
17
2
14
0
11
1
77
30
21
6
11
4
53
34
7
27
1,
39
2
40
49
ye
ar
s
26
(2
4.
8%
)
68
(3
9.
5%
)
64
(4
5.
7%
)
34
(3
0.
6%
)
36
(4
6.
8%
)
8
(2
6.
7%
)
11
6
(5
3.
7%
)
48
(4
2.
1%
)
19
(3
5.
8%
)
10
1
(2
9.
1%
)
15
(5
5.
6%
)
53
5
(3
8.
4%
)
50
59
ye
ar
s
42
(4
0.
0%
)
61
(3
5.
5%
)
36
(2
5.
7%
)
38
(3
4.
2%
)
22
(2
8.
6%
)
10
(3
3.
3%
)
68
(3
1.
5%
)
44
(3
8.
6%
)
17
(3
2.
1%
)
13
9
(4
0.
1%
)
10
(3
7.
0%
)
48
7
(3
5.
0%
)

60
ye
ar
s
37
(3
5.
2%
)
43
(2
5.
0%
)
40
(2
8.
6%
)
39
(3
5.
1%
)
19
(2
4.
7%
)
12
(4
0.
0%
)
32
(1
4.
8%
)
22
(1
9.
3%
)
17
(3
2.
1%
)
10
7
(3
0.
8%
)
2
(7
.4
%)
37
0
(2
6.
6%
)
G
en
de
r
10
5
17
2
14
0
11
1
77
30
21
6
11
4
53
34
7
27
1,
39
2
M
al
e
10
1
(9
6.
2%
)
14
9
(8
6.
6%
)
11
7
(8
3.
6%
)
55
(4
9.
5%
)
72
(9
3.
5%
)
25
(8
3.
3%
)
18
5
(8
5.
6%
)
81
(7
1.
1%
)
50
(9
4.
3%
)
19
2
(5
5.
3%
)
25
(9
2.
6%
)
1,
05
2
(7
5.
6%
)
Fe
m
al
e
4
(3
.8
%)
23
(1
3.
4%
)
23
(1
6.
4%
)
56
(5
0.
5%
)
5
(6
.5
%)
5
(1
6.
7%
)
31
(1
4.
4%
)
33
(2
8.
9%
)
3
(5
.7
%)
15
5
(4
4.
7%
)
2
(7
.4
%)
34
0
(2
4.
4%
)
M
ar
it
al
st
at
us
78
11
0
12
6
84
77
29
15
8
83
50
22
9
17
1,
04
1
M
ar
ri
ed
74
(9
4.
9%
)
10
1
(9
1.
8%
)
11
3
(8
9.
7%
)
67
(7
9.
8%
)
72
(9
3.
5%
)
28
(9
6.
6%
)
14
6
(9
2.
4%
)
74
(8
9.
2%
)
47
(9
4.
0%
)
19
4
(8
4.
7%
)
17
(1
00
%)
93
3
(8
9.
6%
)
Se
pa
ra
te
d/
di
vo
rc
ed
1
(1
.3
%)
2
(1
.8
%)
2
(1
.6
%)
5
(6
.0
%)
3
(3
.9
%)
1
(3
.4
%)
7
(4
.4
%)
2
(2
.4
%)
N
on
e
6
(2
.6
%)
N
on
e
29
(2
.8
%)
W
id
ow
ed
1
(1
.3
%)
7
(6
.4
%)
8
(6
.3
%)
5
(6
.0
%)
N
on
e
N
on
e
4
(2
.5
%)
6
(7
.2
%)
N
on
e
23
(1
0.
0%
)
N
on
e
54
(5
.2
%)
Si
ng
le
/N
ev
er
m
ar
ri
ed
2
(2
.6
%)
N
on
e
3
(2
.4
%)
7
(8
.3
%)
2
(2
.6
%)
N
on
e
1
(0
.6
%)
1
(1
.2
%)
3
(6
.0
%)
6
(2
.6
%)
N
on
e
25
(2
.4
%)
Ed
uc
at
io
n
le
ve
l
78
11
0
12
6
84
77
29
15
7
83
50
22
9
17
1,
04
0
N
o
hi
gh
sc
ho
ol
7
(9
.0
%)
20
(1
8.
2%
)
24
(1
9.
0%
)
24
(2
8.
6%
)
38
(4
9.
4%
)
7
(2
4.
1%
)
31
(1
9.
7%
)
44
(5
3.
0%
)
25
(5
0.
0%
)
17
3
(7
5.
5%
)
5
(2
9.
4%
)
39
8
(3
8.
3%
)
So
m
e
hi
gh
sc
ho
ol
20
(2
5.
6%
)
2
(1
.8
%)
11
(8
.7
%)
7
(8
.3
%)
21
(2
7.
3%
)
13
(4
4.
8%
)
15
(9
.6
%)
6
(7
.2
%)
17
(3
4.
0%
)
N
on
e
1
(5
.9
%)
11
3
(1
0.
9%
)
H
ig
h
sc
ho
ol
gr
ad
ua
te
16
(2
0.
5%
)
10
(9
.1
%)
40
(3
1.
7%
)
24
(2
8.
6%
)
8
(1
0.
4%
)
1
(3
.4
%)
35
(2
2.
3%
)
9
(1
0.
8%
)
7
(1
4.
0%
)
54
(2
3.
6%
)
3
(1
7.
6%
)
20
7
(1
9.
9%
)
Te
ch
ni
ca
lc
ol
le
ge
11
(1
4.
1%
)
23
(2
0.
9%
)
9
(7
.1
%)
4
(4
.8
%)
3
(3
.9
%)
N
on
e
10
(6
.4
%)
2
(2
.4
%)
N
on
e
N
on
e
2
(1
1.
8%
)
64
(6
.2
%)
So
m
e
un
iv
er
si
ty
14
(1
7.
9%
)
8
(7
.3
%)
2
(1
.6
%)
6
(7
.1
%)
6
(7
.8
%)
N
on
e
7
(4
.5
%)
12
(1
4.
5%
)
1
(2
.0
%)
N
on
e
1
(5
.9
%)
57
(5
.5
%)
U
nd
er
gr
ad
ua
te
de
gr
ee
10
(1
2.
8%
)
35
(3
1.
8%
)
28
(2
2.
2%
)
17
(2
0.
2%
)
N
on
e
6
(2
0.
7%
)
50
(3
1.
8%
)
9
(1
0.
8%
)
N
on
e
N
on
e
5
(2
9.
4%
)
16
0
(1
5.
4%
)
Po
st
gr
ad
ua
te
de
gr
ee
N
on
e
12
(1
0.
9%
)
12
(9
.5
%)
2
(2
.4
%)
1
(1
.3
%)
2
(6
.9
%)
9
(5
.7
%)
1
(1
.2
%)
N
on
e
2
(0
.9
%)
N
on
e
41
(3
.9
%)
Em
pl
oy
m
en
t
st
at
us
86
13
3
13
3
10
0
77
30
18
0
92
51
29
0
19
1,
19
1
Em
pl
oy
ed
fu
ll-
/p
ar
t-
ti
m
e4
4
(5
1.
2%
)
81
(6
0.
9%
)
74
(5
5.
6%
)
38
(3
8.
0%
)
52
(6
7.
5%
)
16
(5
3.
3%
)
11
1
(6
1.
7%
)
44
(4
7.
8%
)
28
(5
4.
9%
)
53
(1
8.
3%
)
14
(7
3.
7%
)
55
5
(4
6.
6%
)
U
ne
m
pl
oy
ed
or
re
ti
re
d
32
(3
7.
2%
)
46
(3
4.
6%
)
41
(3
0.
8%
)
39
(3
9.
0%
)
24
(3
1.
2%
)
8
(2
6.
7%
)
55
(3
0.
6%
)
32
(3
4.
8%
)
22
(4
3.
1%
)
15
1
(5
2.
1%
)
3
(1
5.
8%
)
45
3
(3
8.
0%
)
H
om
em
ak
er
10
(1
1.
6%
)
5
(3
.8
%)
17
(1
2.
8%
)
23
(2
3.
0%
)
0
(0
.0
%)
5
(1
6.
7%
)
14
(7
.8
%)
16
(1
7.
4%
)
1
(2
.0
%)
80
(2
7.
6%
)
2
(1
0.
5%
)
17
3
(1
4.
5%
)
D
is
ab
le
d/
ill
ne
ss
N
on
e
1
(0
.8
%)
1
(0
.8
%)
N
on
e
1
(1
.3
%)
1
(3
.3
%)
N
on
e
N
on
e
N
on
e
6
(2
.1
%)
N
on
e
10
(0
.8
%)
Sm
ok
in
g
st
at
us
10
1
11
1
12
6
85
77
29
16
0
83
52
23
6
17
1,
07
7
Cu
rr
en
t
sm
ok
er
s
49
(4
8.
5%
)
69
(6
2.
2%
)
84
(6
6.
7%
)
61
(7
1.
8%
)
47
(6
1.
0%
)
20
(6
9.
0%
)
86
(5
3.
8%
)
65
(7
8.
3%
)
42
(8
0.
8%
)
15
8
(6
6.
9%
)
14
(8
2.
4%
)
69
5
(6
4.
5%
)
Ex
-s
m
ok
er
s
52
(5
1.
5%
)
42
(3
7.
8%
)
42
(3
3.
3%
)
24
(2
8.
2%
)
30
(5
9.
0%
)
9
(3
1.
0%
)
74
(4
6.
2%
)
18
(2
1.
7%
)
10
(1
9.
2%
)
78
(3
3.
1%
)
3
(1
7.
6%
)
38
2
(3
5.
5%
)
S66 A. Sayiner et al.
Algeria
(N = 80)
Egypt
(N = 115)
Jordan
(N = 128)
Lebanon
(N = 91)
Morocco
(N = 77)
Pakistan
(N = 29)
Saudi Arabia
(N = 169)
Syria
(N = 85)
Tunisia
(N = 50)
Turkey
(N = 242)
UAE
(N = 19)
0
20
40
60
80
100
R
e
sp
o
n
d
e
n
ts
 (
%
)
I feel very well or adequately informed about my respiratory condion and its treatment
I feel that I understand completely or mostly the best ways to manage my respiratory condion
Figure 1. Knowledge about COPD by country.
Table 3
Educational needs
How much need do you think there is for better education of people with
respiratory conditions about their condition and its treatment?
N = 1,082
Strong need 905 (83.6%)
Moderate need 129 (11.9%)
Not much of a need 26 (2.4%)
No need at all 22 (2.0%)
How much need do you think there is for better education of doctors and other
health professionals about respiratory conditions?
N = 1,081
Strong need 843 (78.0%)
Moderate need 167 (15.4%)
Not much of a need 34 (3.1%)
No need at all 37 (3.4%)
Knowledge about COPD
Questions related to knowledge about COPD were answered
by between 1,079 and 1,085 subjects in the COPD popula-
tion, accounting for 78% of respondents. Overall, 58.6% of
subjects claimed to be very well or adequately informed
about their respiratory condition and its treatment. This
proportion covered marked differences between countries
(Fig. 1), being lowest in the Maghreb (12.5% in Algeria,
39.0% in Morocco and 54.0% in Tunisia) and highest in
the UAE (78.9%), Lebanon (76.9%) and Jordan (76.6%).
A similar overall proportion of subjects considered that they
understood completely or mostly the best ways to manage
their respiratory condition (52.8%) but here between-
country differences were less marked, ranging from 31.4% in
Turkey to 65.7% in Saudi Arabia.
Respondents considered that there was a strong (83.6%)
or moderate need (11.9%) for better education of people
with respiratory conditions, and a similar high proportion
identiﬁed a strong (78.0%) or moderate need (15.4%) for
better education of health professionals (Table 3). The
proportion of respondents who did not consider that there
was such a need was 12% with respect to both patients and
physicians in all countries.
Overall, 1,026 subjects documented how they were
informed about their COPD. Two-thirds of subjects were
informed by their physicians (66.6%) and the rest by a
third party other than health professionals (Table 4). Of
these, 10.1% claimed to get information from the television
and 6.1% from the internet. Other patients and patient
associations were only cited by eight respondents.
Respondents were asked to identify the underlying cause
of their respiratory condition from a list. Multiple responses
were possible (Fig. 2). However, 412 subjects (29.6%) were
unable to identify an underlying cause and were not sure.
The remaining 980 subjects cited at least one cause.
Overall, 700 (50.3%) identiﬁed smoking as the underlying
cause of their condition and another one in ﬁve identiﬁed
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Table 4
Sources of information. Percentages are calculated with respect to
the 1,026 subjects who responded to this question
Doctors 683 (66.6%)
TV/Cable 109 (10.6%)
Internet 63 (6.1%)
Family and friends 28 (2.7%)
Newspaper 17 (1.7%)
Books 16 (1.6%)
Other patients 6 (0.6%)
Other health professionals 5 (0.5%)
Radio 4 (0.4%)
Magazines 3 (0.3%)
Patient organisations 2 (0.2%)
Nurses 1 (0.1%)
Library None
Other 89 (8.7%)
0% 20% 40% 60% 80% 100%
Not sure
Others
Work related exposures
Polluon
Bronchoconstricon/Tightening of airway muscles
Smoking
Allergies
Redness/swelling of airways
Inﬂammaon of airways
Respondents
Figure 2. Underlying causes of respiratory symptoms as identiﬁed by respondents.
an environmental factor, either pollution or work-related
exposure. Allergies were cited by 8.9% of respondents,
but physiological causes, principally inﬂammation of the
airways, were recognised by less than ten percent of
subjects.
The 700 subjects who recognised smoking as the
underlying cause of their respiratory condition were more
likely to be current smokers (71.9%; N = 503) compared to
subjects who did not recognise this (27.7%; N = 192) and
more likely to have tried unsuccessfully to give up (47.3%;
N = 331 versus 18.6%; N = 129).
Beliefs about COPD and treatment
Respondents were asked whether they agreed with a
number of statements concerning COPD and its treatment.
Essentially two types of response patterns were observed.
Some questions elicited a high agreement rate (>80%) with
little between-country variation, whereas others elicited
a generally lower agreement rate with much variation
between countries (Fig. 3). High agreement was observed
for smoking being the principal cause of COPD, for disease
progression being amenable to treatment, for COPD patients
being able to lead an active life, and for the utility of
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There are no truly eﬀecve treatments for RC
Smoking is the cause of most cases of RC
With proper treatment of RC, progressive
increase in breathlessness can be slowed
RC tends to get worse as you get older,
regardless of treatment
People with RC have be er control of
their disease than ﬁve years ago
With proper treatment most people with RC
can lead a full and acve life
Inhalers are eﬀecve  in providing relief
from symptoms
I always carry an inhaler with me
Having to take medicine twice a day is more
convenient than three or four mes a day
If it was more convenient to take my medicaon,
I would be be er about taking it when I should
Being able to sleep through the night is very
meimportant to
Taking so many medicines in diﬀerent inhalers is
inconvenient
I want a medicaon that allows me to maintain
a normal level of acvity
My current medicaon schedule makes it
diﬃcult to lead an acve life
Respondents
0% 20% 40% 60% 80% 100%
Figure 3. Beliefs about COPD and its treatments. Data are presented as the total proportion of subjects who agreed with the
statements on the left. The black bars indicate the inter-country range between the countries with the lowest and
the highest agreement rates. RC: respiratory condition. The number of respondents to these questions ranged from
672 (inhalers provide relief) to 931 (sleep is very important).
inhalers. On the other hand, there was less consensus with
respect to whether effective treatments existed, whether
deterioration with age was inevitable and whether disease
control had improved over the previous ﬁve years. With
respect to treatments, high agreement was observed for the
importance of maintaining normal activities and getting a
good night’s sleep.
From these responses, a composite variable of ‘optimistic
believers’ was constructed, as described in the Methods
section. Overall, 542 of the 682 respondents for whom this
variable could be calculated (79.5%) fulﬁlled this criterion
of ‘optimistic beliefs’ (Fig. 4). However, response rates for
this question were very low in the three Maghreb countries
of Morocco (10 respondents), Tunisia (2 respondents) and
Algeria (no respondents). In the other countries, the
proportion of optimistic believers varied from 71.6% in
Turkey to 92.3% in Lebanon.
Attitudes to the physician
Overall, 66.8% of respondents stated that they followed
their doctor’s advice on the management and treatment of
their respiratory condition. This proportion was highest in
the Maghreb countries of North Africa (Fig. 5). However,
19.4% stated that they followed this advice rarely or never
(range: 2.1% in Tunisia and Algeria to 25.1% in Turkey).
The overall proportion of patients who found that their
doctor’s advice had helped them in the management of their
symptoms was 47.5% (Fig. 5). The proportion who found the
advice of little or no use was however 25.5% (range: 10.6% in
Tunisia to 37.0% in Turkey).
Respondents were asked whether they agreed with a
number of statements concerning their physician (Fig. 6).
There was high agreement (around 80% of respondents) with
the statements about the physician’s commitment to help,
competence and involvement of the respondent. However,
65.0% of respondents felt that their physician considered
their respiratory condition to be their fault. Less than half
(around 40%) agreed with the assertions about therapeutic
nihilism (My doctor doesn’t think he or she can do anything
to relieve my symptoms ) and empathy (My doctor does not
understand what it is like to suffer from my condition ).
Treatment satisfaction
Respondents were asked to rate their overall satisfaction
with their physician’s management and treatment of
the respiratory condition. For all countries combined,
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Figure 4. Proportion of ‘optimistic believers’ by country.
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I follow my doctor’s advice all or most of the me
My doctor’s advice has helped improve my respiratory symptoms a lot
Figure 5. Attitudes to physician advice by country.
83.2% of respondents were somewhat to very satisﬁed
and 16.8% were somewhat to very dissatisﬁed. There was
little between-country variation for this variable (Fig. 7),
satisfaction rates ranging from 78.3% in Algeria and Egypt to
92.6% in Lebanon.
Determinants of knowledge, treatment satisfaction
and optimistic attitudes
A multivariate logistic regression analysis was performed
to identify demographic, clinical or treatment variables
associated with knowledge about COPD (deﬁned as a
reply of ‘very well informed’ or ‘adequately informed’
to the question about how well informed they considered
themselves about their respiratory condition), treatment
satisfaction (deﬁned as a reply of ‘very satisﬁed’ or
‘somewhat satisﬁed’ to the question about their overall
satisfaction with the management and treatment of their
disease) and optimistic beliefs (deﬁned as the composite
variable described in the Methods section). The results
of this analysis are illustrated in Fig. 8. Extent of
knowledge was associated with male gender (p = 0.04),
using bronchodilators (p = 0.03) and having a low CAT score
(p = 0.04), these respondent groups being more informed.
Treatment satisfaction was associated with not having
exacerbations (p < 0.01). Moreover, treatment satisfaction
was associated with knowledge, subjects who claimed
to be more informed being more satisﬁed with their
management. None of these variables were associated with
having optimistic beliefs. There was a trend, albeit not
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Respondents
My doctor does not understand
what it is like to
suﬀer from my condion
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concerned about helping me
My doctor thinks that
my condion is my fault
My doctor does not think that
it is possible to do anything
to relieve my symptoms
My doctor is very knowledgeable
about my condion and
its treatment
Figure 6. Attitudes to treating physicians. Data are presented as the total proportion of subjects who agreed with the statements
on the left. The black bars indicate the inter-country range between the countries with the lowest and the highest
agreement rates. The number of respondents to these questions was 844.
0
20
40
60
80
100
Algeria
(N = 46)
Egypt
(N = 120)
Jordan
(N = 131)
Lebanon
(N = 95)
Morocco
(N = 74)
Pakistan
(N = 28)
Saudi Arabia
(N = 178)
Syria
(N = 49)
Tunisia
(N = 49)
Turkey
(N = 195)
UAE
(N = 20)
R
e
sp
o
n
d
e
n
ts
 (
%
)
Figure 7. Management and treatment satisfaction by country. Data are presented as the proportion of respondents who reported
being somewhat to very satisﬁed with their doctor’s management and treatment of their respiratory symptoms.
signiﬁcant, for older subjects to be better informed, more
satisﬁed and more optimistic.
Discussion
The BREATHE study has revealed several interesting facets
of perceptions of COPD by subjects with this respiratory
condition in the MENA region. These are in general
consistent with what was observed previously in the USA arm
of the Confronting COPD surveys, of which many of the
questions were subsequently integrated into the BREATHE
detailed COPD questionnaire.
A little over one half of subjects claimed to be very well
or adequately informed about their respiratory condition
and its treatment and to understand completely or mostly
the best ways to manage their respiratory condition.
These proportions are lower than in the Confronting
COPD study performed in the USA a decade previously,
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in which 71% of subjects claimed to understand the
best ways to manage their treatment.5 This relatively
low awareness was supported by several incorrectly held
beliefs or inappropriate behaviours. For example, four
subjects out of ten believed that there were no truly
effective treatments and eight out of ten believed that
their respiratory condition would get progressively worse
regardless of treatment. Thirty percent of subjects were
unsure what had caused their respiratory problems. One
patient out of two did not carry an inhaler around
and two out of three were still smoking. Attitudes to
smoking showed a revealing discordance between the 81% of
respondents who believed that smoking was the cause of
most cases of COPD in general and the 51% who accepted
that it was the cause of their own respiratory problems.
The majority of respondents who considered smoking to be
the cause of their disease were current smokers, and around
half of these had previously attempted to give up smoking,
compared with only 19% of subjects who did not consider
smoking to be the cause of their problems. This suggests that
subjects who were aware of the consequences of smoking on
their respiratory health were more likely to make efforts to
stop smoking.
The physician was the principal source of information on
respiratory problems cited by respondents. However, around
one third did not receive information from their physician,
and ten percent got their information from the television,
which may not be the most accurate source. Provision of
reliable alternative parallel sources of information may
be a relatively simple and inexpensive way of improving
awareness for patients with COPD. For example, in
other disease areas, patient associations provide leaﬂets,
telephone help lines or opportunities for patients to meet
and share experiences, which are useful for building
patient knowledge and setting realistic expectations about
treatment. In the BREATHE study, patient associations were
virtually never cited as a source of information, suggesting
that these do not exist or, if they do, that they do not play
an important role in patient information in the countries of
the region. Reliable websites in local languages, perhaps
supervised by local chest medicine societies, could also
provide a channel for directing accurate information about
COPD and its treatment to patients. Although use of the
internet by the age group concerned (over forty years)
is currently rather infrequent in the MENA region, this
situation will change in coming years as people who have
grown up with the internet will spontaneously look here
for information. In North America, the notion of ‘patient
empowerment’ has been inﬂuential in inciting patients to
become ‘experts’ on their disease, and parallel information
sources are widely used. This may contribute to why the
proportion of subjects who claimed to understand their
disease was higher in the USA than it was in the BREATHE
study. In the MENA region, on the other hand, a more
traditional physician patient relationship is likely to persist
in which patients look primarily to their physician as the
authority on their disease. However, this may be considered
to be an opportunity for the physician to encourage patients
to learn about their disease and to orientate them towards
appropriate sources of information. As in the US study, over
ninety percent of respondents declared that there was a
need for better education of patients with COPD, so it is
likely that they would be receptive to any initiative from
physicians or third parties to increase disease awareness.
Although 86% of the BREATHE subjects were satisﬁed
with the way their physician was managing their disease,
this is likely to be indicative of low expectations rather
than optimal treatment. Half of the respondents, even
if they were satisﬁed with their treatment, declared
that their doctor’s advice had not in fact helped them
in the management of their symptoms. In addition, as
described in other articles in this supplement, respondents
were considerably disabled by their respiratory condition,
frequently hospitalised and prevented from working.12,13
A high level of treatment satisfaction associated with
poor disease control was also observed in Confronting
COPD .5 Although the great majority of respondents of
the BREATHE study (90.5%) believed that, with proper
treatment, most people with COPD can lead a full and
active life, 57% of respondents recognised that their own
treatment schedule made it difﬁcult to lead an active life.
This gap between what subjects believe that treatments can
offer and how they are actually treated is troubling and it
is important for physicians to encourage their patients to
tell them about residual symptoms and disability so that
treatment can be changed if necessary. In this context,
regular assessment with a simple patient questionnaire
such as the CAT may help inform physicians as well as
patients about the level of well-being and the potential for
further improvement. Although ﬁnancial and other barriers
to optimal treatment may exist for certain patients with
COPD in the MENA region, the quality of life of many could be
expected to improve with a more dynamic physician patient
dialogue aimed at optimising symptom control.
Over eighty percent of respondents agreed that use of
inhalers was effective in improving symptoms, that people
with COPD, if properly treated, can lead a full and active
life, that the progressive increase in breathlessness can be
slowed, and that people with COPD have better control
of their disease than they did ﬁve years previously. This
reﬂects a generally optimistic attitude to COPD and its
management, as was also noted in Confronting COPD .5
In addition, a similar proportion of subjects considered
that their physicians were concerned about helping them,
were knowledgeable about COPD and involved their patients
in treatment decisions. This positive attitude should
be considered as an opportunity for improving patient
awareness and involving patients more fully in shared
decision-making with their physicians.
Given that social and economic conditions, as well
as access to healthcare, differ considerably between
participating countries, it was of interest to consider
whether any of the between-country variation in attitudes
and beliefs identiﬁed in the BREATHE study could be related
to such differences. Table 5 provides information on social
and economic indicators in participating countries obtained
from UNESCO14 or the IMF.15 Some possible relationship
was noted between how well respondents felt that they
were informed about the disease and educational level. The
proportion of respondents obtaining a highschool diploma or
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Table 5
Social and economic indicators for participating countries
Algeria Egypt Jordan Lebanon Morocco Pakistan Saudi
Arabia
Syria Tunisia Turkey UAE
Literacy ratea 75.4% 66.4% 91.1% 89.7% 56.1% 58.2% 86.1% 84.2% 77.7% 90.8% 90.0%
Subjects with high school
diploma (%)b
65.4% 80.0% 72.2% 63.1% 23.4% 31.0% 70.7% 39.8% 16.0% 24.5% 64.7%
Per capita annual GDP
(US$×1,000) c
3.2
6.4
1.6
3.2
3.2
6.4
6.4
12.8
1.6
3.2
0.8
1.6
25.6
51.2
1.6
3.2
3.2
6.4
6.4
12.8
51.2
102.4
Access to public healthcare
reimbursement
Yes No No No No No Yes No No Yes Yes
a Source: UNESCO.14
b Source: information collected in the BREATHE study concerning adults aged 40 years only.
c Source: IMF.15
higher level of education was highest in Jordan, Lebanon
and Egypt, and these are countries where respondents
considered themselves best-informed. In contrast, the
countries with the lowest proportion of highschool graduates
in this age group (the Maghreb countries and Turkey) were
those where the proportion of respondents considering
themselves well-informed was the lowest. A similar trend
was observed for the proportion of respondents who were
aware that smoking was the principal risk factor for COPD.
Somewhat surprisingly, there was no obvious relationship
between treatment satisfaction, which was very similar
across countries, and access to reimbursement for public
healthcare. This may reﬂect low treatment expectations
on the part of the patients, since most are not managed
appropriately,12 or a feeling of fatality about their disease.
Indeed, most of the respondents in all countries thought that
their disease was going to get worse, regardless of whether
they were treated.
In conclusion, the perceptions of COPD and its treatment
which have been documented in the BREATHE study suggest
that awareness of the disease is suboptimal and treatment
expectations are undervalued in the MENA region. Better
patient education and more effective patient physician
communication are clearly required and the opening up
of alternative information channels may complement the
patient physician dialogue.
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